Kornimate/medical-research-clean huggingface dataset:
immunophenotyping of blast cells and immune effector cells in peripheral whole blood and bone marrow samples from aml and mds patients (aml)

Conditions: Leukemia

Summary: the objective of this study is to evaluate the immune profile of blast cells and immune effector cells in paired peripheral whole blood and bone marrow samples from aml and mds patients by standardized flow cytometry. a special emphasis will be focused on monitoring expression of cd200 as well as pgp-170 (mdr1) on blasts cells.


Eligibility criteria:
inclusion criteria: * age \> 18 * no pregnant woman * patient with myelodysplastic syndrome (with excess blasts) or acute myeloid leukemia * presence of a monitored serum blastose * patient who can obtain free and informed consent (speaks french, no guardianship or curatorship) exclusion criteria: * minor patient (\< 18 years old) * medical or psychological condition that could interact with the ability to understand the study, * pregnant or lactating women, * major persons under guardianship or under the protection of justice * persons deprived of their liberty by a judicial or administrative decision * lack of information and opposition to its participation in the study
a prospective multicenters clinical cohort study of stratified treatment of chinese children with systemic alk(+) alcl

Conditions: MRD; MDD; Lymphoma, Nonhodgkin; Anaplastic Lymphoma; Pediatric Cancer

Summary: with the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-hodgkin lymphoma (nhl) in children. in recent years, the criteria for clinical staging and efficacy evaluation of nhl in children have been updated. studies in germany and the united states have shown that pathological types of systemic anaplastic large cell lymphoma (alcl) in children and adolescents, minimal disseminated disease (mdd) in peripheral blood or bone marrow and minimal residual disease (mrd) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of alcl patients. recent studies have also suggested that pet/ct is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. in order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of nhl in children. we adjusted the original nhl-bfm-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen，etc.

research purpose: 1. to study the efficacy and safety of scccg-alcl-2017 regimen in children with systemic alk-positive anaplastic large cell lymphoma. 2. to explore the correlation between mdd or mrd in peripheral blood or bone marrow and the treat response and survival. 3. to explore the feasibility of risk stratification combined with adverse pathological types, dangerous organ invasion and mdd. 4. to investigate the effect of vinblastine maintenance chemotherapy on survival of patients with mrd-positive in peripheral blood after treatment.

Eligibility criteria:
inclusion criteria: 1. age \< 18 years old 2. pathologically confirmed systemic alk-positive anaplastic large cell lymphoma 3. newly diagnosed patients 4. informed consent of guardian of children patients exclusion criteria: 1. secondary immunodeficiency disease 2. second neoplasm 3. primary cutaneous anaplastic large cell lymphoma 4. recurrent and progressive patients.
sbs disk- creation of a quality of life tool for short bowel patients compared with a validated quality of life questionnaire (sbs qol)

Conditions: Short Bowel Syndrome

Summary: patients with short bowel syndrome have an impact on their quality of life because they need temporary or permanent parenteral nutritional support. the quality of life of these patients has been the subject of several studies and assessment tools exist, such as the short bowel syndrome quality of life (sbs qol). this tool may seem complex and tedious to use in everyday practice. however, it is important to regularly assess the quality of life of these patients. this is why the investigators are proposing to create a new tool for more rapid assessment of the quality of life of patients with short bowel syndrome.


Eligibility criteria:
inclusion criteria: * age 18 or over * patient able to read and speak french * patient suffering from short bowel syndrome exclusion criteria: * known cognitive disorders

Keywords: short bowel syndrome quality of life
screening versus routine practice in detection of atrial fibrillation in the elderly population of lieto

Conditions: Atrial Fibrillation; Stroke

Summary: the aim of this study is to evaluate the feasibility of patient education on feeling the own pulse irregularity in the elderly population of lieto. prevalence of atrial fibrillation (af) rises with age. subjects have often symptoms like palpitation and discomfort but especially in elderly population there's significant quantity of persons who don't feel any symptoms and fail to seek for medical care for stroke prevention. the main objectives in this study are to find out the prevalence of af in the elderly population of lieto, to assess the feasibility and reability of patient education on feeling one's pulse irregularity and the affect to the quality of life of the participating subjects and monitoring the possible increased burden to the public health care system. the study contains two office visits with specified learning session and long-term phone-call follow-up.

the main objectives in this study are to find out the prevalence of af in the elderly population of lieto, to assess the feasibility of patient education on feeling one's pulse irregularity and the affect to the quality of life of the participating subjects and monitoring the possible increased burden to the public health care system. the study contains two office visits with specified learning session and long-term phone-call follow-up. a specially trained nurse will initially give a 10 min education on pulse palpation to each person and evaluate their capacity to learn pulse palpation. during followup visits the compliance of the patient and possible new arrhythmias plus quality of life issues are recorded and their ability of pulse palpation is evaluated by artificial hand where various kinds of pulses are transmitted.

Eligibility criteria:
inclusion criteria: * patient aged 75 or over * inhabitant of lieto * willing to participate exclusion criteria: * chronic atrial fibrillation * ongoing anticoagulant treatment * permanent institutional care

Keywords: atrial fibrillation thromboembolism patient education
study of s-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to determine whether s-1 and oxaliplatin as neoadjuvant chemotherapy may improve survival benefit compared with control.


Eligibility criteria:
inclusion criteria: 1. disease characteristics: histologically confirmed gastric adenocarcinoma locally advanced disease:clinical stage t3-4, n0-3, m0 (according to the japanese gastric cancer classification) 2. planning to undergo gastric cancer d2 surgery after neoadjuvant chemotherapy 3. age:20 to 75 4. performance status:ecog 0-2 5. life expectancy:not specified 6. hematopoietic:wbc 4,000-12,000/mm\^3；granulocyte count ≥ 2,000/mm\^3；platelet count ≥ 100,000/mm\^3；hemoglobin ≥ 9.0 g/dl;hepatic:ast and alt ≤ 100 u/l；bilirubin ≤ 1.5 mg/dl 7. adequate organ function 8. able to swallow oral medication 9. written informed consent exclusion criteria: 1. synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2. pregnant or breast-feeding women 3. severe mental disease 4. systemic administration of corticosteroids, flucytosine, phenytoin or warfarin 5. other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, or ischemic heart disease 6. myocardial infarction within six disease-free months
prophylactic mirtazapine and different doses of intrathecal morphine in preventing nausea and vomiting after cesarean section

Conditions: Prophylactic; Mirtazapine; Intrathecal; Morphine; Nausea; Vomiting

Summary: the aim of this work was to evaluate the role of prophylactic mirtazapine and different doses of intrathecal morphine in preventing nausea and vomiting.

it is common practice to provide intrathecal morphine to alleviate postoperative pain because of its powerful and long-lasting analgesic effects. mirtazapine is a noradrenergic and specific serotonergic antidepressant. it is anxiolytic by its antagonist of the 5ht2 receptor and is strongly sleep-inducing. its antagonist at 5-hydroxytryptamine subtype 3 (5-ht3) receptor may help to prevent nausea and vomiting

Eligibility criteria:
inclusion criteria: * age 18-40 years. * american society of anesthesiologists (asa) physical status i-ii. * scheduled for caesarean section under spinal anesthesia exclusion criteria: * known hypersensitivity to mirtazapine. * gastrointestinal illness. * diabetes mellitus. * use of opioids or any medication with known antiemetic properties within 48 hours before surgery. * mental disorders. * spinal anesthesia contraindications. * taking antidepressants or antipsychotic medications.
central serous chorioretinopathy and micropulse laser treatment

Conditions: Central Serous Chorioretinopathy

Summary: to evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with acetazolamide and/or eplerenone


Eligibility criteria:
inclusion criteria: * diagnosis of central serous chorioretinopathy (csc) with no response to conservative therapy, consisted in acetazolamide and eplerenone after six months. * foveal serous retinal detachment for at least 6 months. * minimum age of 18 years old at the screening time * reading and comprehension skills of informed consent exclusion criteria: * previous retinal treatment for csc, except for acetazolamide and eplerenone * no diffuse retinal epitheliopathy * other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization * not controlled glaucoma with eyedrops, or advanced glaucoma * myopia or hypermetropia greater than 6 diopters * opacities of dioptric media * low quality of optical coherence tomography (oct) and oct-angiography scans * low quality images of fluorescein angiography and indocyanine green angiography * no written consensus signed.
spontaneous breathing trial with t-piece or inspiratory pressure augmentation

Conditions: Ventilator Weaning

Summary: weaning is an important process to gradually separate mechanically ventilated patients from ventilators. a good weaning strategy aims to early identify mechanically ventilated patients who are ready for extubation but not to prematurely extubate them. spontaneous breathing trial (sbt) is a test to assess the patient's ability to breathe spontaneously when extubated. several methods have been used to conduct an sbt, including t-piece breathing, low-level pressure support ventilation (psv) of 5-7 cm h2o, continuous positive airway pressure and automatic tube compensation (atc). the investigators hypothesized that an sbt with inspiratory pressure augmentation increases initial sbt success, reduces the length of invasive mechanical ventilation (imv) support and does not increase reintubation risk as compared with t-piece, which result in a higher proportion of patients successfully liberated from imv in the inspiratory pressure augmentation group. however, inspiratory pressure augmentation significantly reduces work of breathing on an sbt as compared with t-piece. patients extubated following an sbt with inspiratory pressure augmentation may experience increased respiratory effort after extubation and this may increase the use of noninvasive ventilation after extubation. an sbt with inspiratory pressure augmentation increases imv free days but not mv free days as compared with t-piece. longer imv free days may be associated with a lower mortality due to fewer imv related complication. this study is a pragmatic, cluster-randomized, multiple crossover, multicenter trial to compare sbts with t-piece versus inspiratory pressure augmentation in weaning outcomes. mechanically ventilated patients who meet the criteria for readiness to sbt will be included. the patients will use either t-piece or inspiratory pressure augmentation as sbt for weaning according to an icu-based cluster randomization and crossover sequence.


Eligibility criteria:
inclusion criteria: 1. admitted to the adult intensive care unit (icu) 2. receiving invasive mechanical ventilation via an endotracheal tube 3. ready to start an sbt\* \*the criteria of readiness to an sbt include fio2 ≤ 0.4, peep ≤ 8 cmh2o, minute ventilation ≤ 0.15 l/min/predicted body weight, inspiratory pressure or driving pressure ≤ 14 cm h2o, stable cardiovascular status and no worsening of non-pulmonary organ function. exclusion criteria: 1. age \< 20 years 2. receiving mechanical ventilation via tracheostomy 3. mechanical ventilation \< 12 hours 4. invasive ventilation started before the index hospitalization 5. on do-not-intubate order

Keywords: clinical trial mechanical ventilation respiratory failure spontaneous breathing trial weaning
sd01 master study (safety and efficacy study)

Conditions: Ventricular Tachycardia; Ventricular Fibrillation; Heart Failure

Summary: the study is designed to confirm safety and efficacy of the sd01 icd (implantable cardioverter-defibrillator) lead.


Eligibility criteria:
inclusion criteria: * standard indication for an icd/crt-d therapy * signed informed consent form * patient is willing and able to participate for the whole study duration * patient is willing and able to activate and use the cardiomessenger * legal capacity and ability to consent. exclusion criteria: * standard contraindication for an icd/crt-d therapy * age \<18 years. * pregnant or breastfeeding * cardiac surgery is planned within the next six months * any condition that in the opinion of the investigator would preclude compliance with the study protocol during the whole follow-up period * enrollment in another cardiac clinical investigation with active treatment arm * mechanical tricuspid valve prosthesis or severe tricuspid valve disease * dexamethasone acetate intolerance
clinical efficacy of platelet transfusion

Conditions: Thrombocytopaenia; Haematological Malignancies

Summary: the aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.

since 2017, the preparation processes and shelf life of platelet concentrates (pcs) have been changed to increase transfusion safety and optimise transfusion processes. these changes have led to an increase in the total number of pcs transfused, a decrease in the number of platelets per pc and an increase in the number of platelets transfused per patient. previous studies have shown that longer storage of platelets contributes to less in vivo recirculation of transfused platelets. studies of haemostatic efficacy have generally not reported a significant effect. however, the haemostatic efficacy of pc stored for more or less than 5 days has not been evaluated. the eclat multicentre prognostic cohort study will prospectively and comparatively evaluate the haemorrhagic event in haematology patients with severe thrombocytopenia transfused according to the duration of pc storage.

Eligibility criteria:
inclusion criteria: * patients with haematological malignancies or bone marrow aplasia with severe thrombocytopenia due to bone marrow failure related to the disease or treatments received * severe thrombocytopenia requiring transfusion * patient able to self-assess bleeding events * non-opposition of the subject to participate in the study * registered with the french social security system or benefiting from such a system. exclusion criteria: * acute promyelocytic leukaemia * curative dosage of anticoagulants * treatment with antiplatelet agents * patient with proven thrombocytopenia of immunological origin, or disseminated intravascular coagulation * patients with a clinically significant haemorrhagic event (who grade 2) in the 48 hours prior to transfusion * indication for deplasmatised, cryopreserved and reduced-volume pcs * patient refusing transfusion of labile blood products * pregnant women or breast-feeding mothers * adults subject to a legal protection measure or unable to express their consent * persons deprived of their liberty by a judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social care institution for purposes other than research * subject in the exclusion period of another study

Keywords: platelet concentrate transfusion haemorrhage
feasibility and benefits of reflexology in the prevention of neuropathy induced by oxaliplatin in colorectal cancer

Conditions: Colorectal Cancer

Summary: the management of colorectal cancer often requires oxaliplatin-based chemotherapy, either as part of curative treatment plans or exclusively in palliative situations. oxaliplatin therefore plays a key role in the management of colorectal cancer. in addition to its digestive and hematological toxicity, oxaliplatin frequently induces chronic, often limiting, sensitive peripheral neuropathy. only early discontinuation of oxaliplatin can limit the risk of clinically limiting neurotoxicity (grade ≥ 3). in oncology, managing the side-effects of treatment is an essential objective of supportive care, and is open to a variety of complementary medicines, including reflexology. this technique, derived from traditional chinese medicine, involves stimulating reflex points on the arch of the foot.

this first monocentric, prospective pilot study is designed to evaluate if the intervention is feasible in routine clinical practice for patients initiating bimonthly oxaliplatin chemotherapy for colorectal cancer. it will also provide initial estimates of the parameters needed to measure efficacy and impact on patient quality of life. patients will receive a reflexology session with each cycle of chemotherapy, and will be assessed during all the treatment period.

Eligibility criteria:
inclusion criteria: * age\>18 years treated for colorectal cancer in digestive oncology service rangueil hospital * initiation of intravenous oxaliplatin chemotherapy at 85 mg/m² on a bimonthly schedule. * ability to understand and answer a self-questionnaire. * life expectancy egal or over 12 weeks * signed informed consent form exclusion criteria: * pre-existing motor and/or sensitive neuropathy. * reflexology treatment within the last 6 months. * contraindication to reflexology: venous thrombosis, trauma, wound or metastasis of the foot. * patient covered by a legal protection scheme.

Keywords: oxaliplatin reflexology
the effect of virtual reality exercises on balance in patients with osteoporosis

Conditions: Osteoporosis

Summary: osteoporosis is a systemic disease characterized by low bone mass and increased bone fragility and increased fracture likelihood as a result of deterioration of the bone tissue microstructure.one of the important conditions determining the fracture risk in osteoporosis patients is fall. balance exercises are perform to reduce the risk of falling.virtual reality games are used in balance studies in many rehabilitation areas. the aim of this study is to investigate the effect of virtual reality exercises on balance.

osteoporosis is a systemic disease characterized by low bone mass and increased bone fragility and increased fracture likelihood as a result of deterioration of the bone tissue microstructure.one of the important conditions determining the fracture risk in osteoporosis patients is fall. balance exercises are perform to reduce the risk of falling.virtual reality games are used in balance studies in many rehabilitation areas. the aim of this study is to investigate the effect of virtual reality exercises on balance patients with osteoporozis.

Eligibility criteria:
inclusion criteria: * diagnosed with primary osteoporosis exclusion criteria: * history of inflammatory rheumatic disease * history of vestibular and cerebellar disease * diseases affecting the central and peripheral nervous system (parkinson's, stroke, ataxia, dementia, multiple sclerosis, peripheral neuropathy
feasibility and safety of delivering a ketone drink to comatose survivors of out-of-hospital cardiac arrest

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: every year, efforts are made to resuscitate about 30,000 people when their hearts stop outside of the hospital environment ('out-of-hospital cardiac arrest'). early damage to the brain due to 'oxygen starvation' (seemingly paradoxically) gets worse when blood flow is restored. of the 6,350 survivors admitted to intensive care units, 46% die from brain damage, and half of those who survive suffer long-term brain damage. apart from avoiding a high temperature, nothing has been found which can protect the brain or improve outcome. 'ketones' are chemicals naturally produced in the body from fat during starvation. they act as an energy source, but also as regulators of metabolism, and appear to protect cells from damage when oxygen supplies are scarce, or when blood flow is restored. the investigators want to see whether a ketone drink will protect the brain after out-of-hospital cardiac arrest. the investigators will study 10 cardiac arrest patients, and participants will be given the ketone drink via a feeding tube (which is routinely passed into the stomach in such cases). the investigators shall check that the drink is absorbed, and measure the ketone levels in the blood. the investigators will also measure important aspects of blood chemistry (including ph and blood sugar) and collect data on brain (electrical recordings called 'eeg' and 'ssep') and heart function (ultrasound scans or 'echocardiographs') - both of which it is hoped might improve - in order to demonstrate that this is possible if it is to be included in a subsequent large trial. the study will be scrutinised by world experts in the field, who have also helped design the study. if this pilot study is a success, the investigators will apply to a major grant body to fund an appropriately-powered randomised controlled trial to determine whether ketones improve neurological outcome and survival in these patients. results will also allow similar studies to be planned in heart attack, stroke and traumatic brain injury.


Eligibility criteria:
inclusion criteria: * aged 18 years or above * male or female * comatose survivors of out-of-hospital cardiac arrest, defined as return of spontaneous circulation for at least 5 minutes with a score of \<8 on the glasgow coma scale * for admission to intensive care unit for full, active treatment exclusion criteria: * primary neurological or intracranial cause of cardiac arrest * in-hospital cardiac arrest * inclusion in another trial at time of recruitment * over 4 hours from time of return of spontaneous circulation to enrollment